吡嗪酰胺对结核杆菌的作用方式-猫眼课题宝

吡嗪酰胺对结核杆菌的作用方式

批准号：

7557844

负责人：

YING ZHANG

金额：

$30.51万

依托单位：

JOHNS HOPKINS UNIVERSITY

依托单位国家：

美国

项目类别：

财政年份：

1998

资助国家：

美国

项目状态：

已结题

起止时间：

1998-12-01 至 2011-01-31

来源：

https://reporter.nih.gov/project-details/7557844

关键词：

Acids Aconitate Hydratase Address Aerobic Affect Age Antibiotics Antitubercular Agents Bacillus (bacterium)Biochemical Genetics Cells Clinical Treatment Development Drug Resistant Tuberculosis Drug effect disorder Drug resistance Energy Metabolism Enhancers Enzymes Funding Gene Expression Gene Expression Profiling Generations Goals Iron Knowledge Laboratories Light Membrane Membrane Potentials Microarray Analysis Molecular Profiling Mus Mutation Mycobacterium tuberculosis NADH dehydrogenase (ubiquinone)Nature Nutrient Omeprazole Outcome Study Oxygen Pharmaceutical Preparations Phase Play Predisposition Principal Investigator Prodrugs Production Progress Reports Property Proton-Translocating ATPases Pyrazinamide Pyrazinamide resistance Research Personnel Reserpine Resistance Respiratory Chain Role Starvation Testing Transmembrane Transport Tuberculosis Work aged base chemotherapy comparative cytochrome c oxidase design improved in vitro activity in vivo interest killings programs pyrazinamide deamidase pyrazinoic acid resistance mechanism resistant strain response tool tuberculosis drugs tuberculosis treatment

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

DESCRIPTION (provided by applicant): Pyrazinamide (PZA) is an important frontline tuberculosis (TB) drug that is involved in shortening the TB therapy. PZA is an unconventional and paradoxical drug. Despite its powerful sterilizing activity in vivo and its importance in achieving the short course therapy, PZA has no activity against M. tuberculosis under normal culture conditions but is active at acid pH, and PZA kills nongrowing bacilli more effectively than actively growing bacilli. The recent interest to develop new TB drugs that can shorten the therapy has highlighted the importance to understand the mode of action of PZA. Although PZA has been used in clinical treatment of TB since 1952 -the same year as INH, its mode of action is the least understood of all TB drugs because of the paradoxical nature of PZA. Work from this laboratory supported by this application has resulted in a number of significant findings about the mode of action of PZA. Based on these observations, we hypothesize that pyrazinoic acid (POA), the active form of PZA, targets the membrane and interferes with membrane energetics. In this application, we propose the following specific aims to further our understanding of this important TB drug: (1) To investigate the effect of factors that affect membrane energy metabolism on the activity of PZA/POA against M. tuberculosis. These factors include: low oxygen, weak acids, starvation, respiratory chain enzymes and aconitase (2) To assess the effect of enhancers of PZA activity on further improving the sterilizing activity of PZA against M. tuberculosis in vivo in mice, (3) To identify new mechanisms of PZA action and resistance by comparing the gene expression profiles of resistant strains without pncA mutations with sensitive strain in response to PZA. These studies will improve our understanding of mechanisms of PZA action and resistance and should have implications for the design of new antituberculosis drugs that can shorten the TB therapy.

期刊论文(46)

专著(0)

科研奖励(0)

会议论文